• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email
    SC 13G/A 1 tm2427858d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)

     

    Zymeworks Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    98985Y108

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x  Rule 13d-1(b)

     

      ¨  Rule 13d-1(c)

     

      ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 98985Y108

     

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (A) ¨

    (B)  ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

     

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    5,101,911 (1)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    5,101,911 (1)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,101,911 (1)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    7.2% (2)

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common shares (“Common Stock”) is comprised of 5,101,911 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC (collectively, the “Redmile Clients”), which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (2) Percentage based on 71,047,390 shares of Common Stock outstanding as of July 31, 2024, as reported by the Issuer in its Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 1, 2024 (the “Form 10-Q”).

     

     

     

     

    CUSIP No. 98985Y108

     

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (A)  ¨

    (B)  ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

     

     

     

     

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    5,101,911 (3)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    5,101,911 (3)

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,101,911 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    7.2% (4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

     

    (3) Jeremy C. Green’s beneficial ownership of the Common Stock is comprised of 5,101,911 shares of Common Stock owned by certain Redmile Clients, which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of such Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

    (4) Percentage based on 71,047,390 shares of Common Stock outstanding as of July 31, 2024, as reported by the Issuer in the Form 10-Q.

     

     

     

     

    Item 1.

     

      (a) Name of Issuer
         
        Zymeworks Inc.
         
      (b) Address of Issuer’s Principal Executive Offices
         
        108 Patriot Drive, Suite A
        Middletown, Delaware 19709

     

    Item 2.

     

      (a) Names of Persons Filing
       
        Redmile Group, LLC
    Jeremy C. Green
       
      (b) Address of Principal Business office or, if None, Residence
       
        Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129
       
        Jeremy C. Green
    c/o Redmile Group, LLC (NY Office)
    45 W. 27th Street, Floor 11
    New York, NY 10001

     

    (c) Citizenship
     
        Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom
     
    (d) Title of Class of Securities
     
        Common Stock, par value $0.00001 per share
     
    (e) CUSIP Number
     
        98985Y108

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

     

     

     

      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4. Ownership.

     

      (a) Amount beneficially owned:
       
        Redmile Group, LLC – 5,101,911 (1)
    Jeremy C. Green – 5,101,911 (1)
       
      (b) Percent of class:
       
        Redmile Group, LLC – 7.2% (2)
    Jeremy C. Green – 7.2% (2)
       
      (c) Number of shares as to which Redmile Group, LLC has:

     

      (i) Sole power to vote or to direct the vote:

     

        0

     

      (ii) Shared power to vote or to direct the vote:

     

        5,101,911 (1)

     

      (iii) Sole power to dispose or to direct the disposition of:

     

        0

     

      (iv) Shared power to dispose or to direct the disposition of:

     

        5,101,911 (1)

     

      Number of shares as to which Jeremy C. Green has:

     

      (i) Sole power to vote or to direct the vote:

     

        0

     

      (ii) Shared power to vote or to direct the vote:

     

        5,101,911 (1)

     

     

     

     

      (iii) Sole power to dispose or to direct the disposition of:

     

        0

     

      (iv) Shared power to dispose or to direct the disposition of:

     

        5,101,911 (1)

     

      (1) The Issuer’s common shares reported herein are held by certain Redmile Clients for which Redmile Group, LLC is the investment manager/adviser and, in such capacity, exercises voting and investment power over all of the common shares held by the Redmile Clients and may be deemed to be the beneficial owner of these shares. Jeremy C. Green serves as the principal of Redmile Group, LLC and also may be deemed to be the beneficial owner of these shares. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

      (2) Percentage based on 71,047,390 shares of Common Stock outstanding as of July 31, 2024, as reported by the Issuer in the Form 10-Q.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

      N/A.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

      See the response to Item 4.

     

    Item 8. Identification and Classification of Members of the Group.

     

      N/A.

     

    Item 9. Notice of Dissolution of Group.

     

      N/A.

     

    Item 10. Certifications.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024

     

      Redmile Group, LLC  
         
      By: /s/ Jeremy C. Green
        Name: Jeremy C. Green
        Title: Managing Member

     

        /s/ Jeremy C. Green
        Jeremy C. Green  

     

     

     

    Get the next $ZYME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    6/9/2026$28.00Buy
    Truist
    12/12/2025$33.00Equal Weight → Overweight
    Wells Fargo
    12/3/2025$32.00Mkt Outperform
    Citizens JMP
    10/24/2025$15.00Equal Weight
    Wells Fargo
    10/14/2025$26.00Neutral → Buy
    H.C. Wainwright
    10/10/2025$30.00Buy
    B. Riley Securities
    5/20/2025Buy
    TD Cowen
    12/16/2024$18.00Neutral → Overweight
    Analyst
    More analyst ratings

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Operating Officer Hollywood Mark was granted 939 shares, increasing direct ownership by 0.71% to 133,852 units (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    7/6/26 5:29:24 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, General Counsel Schneider Paul R

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/15/26 5:00:04 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Schneider Paul R claimed no ownership of stock in the company (SEC Form 3)

    3 - Zymeworks Inc. (0001937653) (Issuer)

    5/15/26 4:55:04 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    SEC Filings

    View All

    Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Zymeworks Inc. (0001937653) (Filer)

    6/29/26 7:20:20 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Zymeworks Inc.

    SCHEDULE 13G/A - Zymeworks Inc. (0001937653) (Subject)

    5/15/26 4:09:19 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Zymeworks Inc. (0001937653) (Filer)

    5/14/26 4:29:55 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Truist resumed coverage on Zymeworks with a new price target

    Truist resumed coverage of Zymeworks with a rating of Buy and set a new price target of $28.00

    6/9/26 8:30:10 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00

    12/12/25 8:37:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Zymeworks with a new price target

    Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00

    12/3/25 8:41:52 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/19/25 6:35:05 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/18/25 3:17:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/7/25 6:34:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

    VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026. In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second quarter earnings conference call after release of its financial results. We look forward to providing an update following the expected closing of the proposed acquisition of Theravance Biopharma, shar

    7/16/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

    Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development candidates into pre-IND development in 2027.SAN FRANCISCO, July 6, 2026 /CNW/ -- American News Group News Commentary, Artificial intelligence has become a fixture in biotech marketing, but the more consequential question is where it is actually used: in the slide deck, or at the bench. GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company, says it is applying AI to the latter, embedding AI-bas

    7/6/26 11:19:00 AM ET
    $CTMX
    $GTBP
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks to Acquire Theravance Biopharma, Inc.

    Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected growthTransaction financed primarily by $350 million non-recourse note secured solely by U.S. YUPELRI® profit s

    6/29/26 6:00:00 AM ET
    $ZYME
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    View All

    Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

    • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer  VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "These appointments come at a pivotal time for Zymeworks as we e

    4/9/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Kristin Stafford as Chief Financial Officer

    VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the appointment of Ms. Kristin Stafford as Chief Financial Officer, effective April 1, 2026. "Kristin brings deep experience across the life sciences industry, with a strong track record in strategic planning, disciplined capital allocation, and executing complex capital markets and strategic transactions, including acquisitions, during her time at Royalty Pharma," said Kenneth Galbraith, Chair and Chief Executive Officer. "We a

    4/1/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

    VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks' Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovati

    11/18/25 1:01:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Financials

    Live finance-specific insights

    View All

    Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

    VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026. In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second quarter earnings conference call after release of its financial results. We look forward to providing an update following the expected closing of the proposed acquisition of Theravance Biopharma, shar

    7/16/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks to Acquire Theravance Biopharma, Inc.

    Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing structure that enhances shareholder value by minimizing Zymeworks’ net capital at risk Transaction expected to be accretive to earnings and cash flow upon closing. YUPELRI® U.S. profit share and ex-U.S. royalties generate ~$60 million annualised cash flow at current run-rates, with continued expected growthTransaction financed primarily by $350 million non-recourse note secured solely by U.S. YUPELRI® profit s

    6/29/26 6:00:00 AM ET
    $ZYME
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

    VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2026 financial results after market close on May 7, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 7, 2026 at 4:30 pm Eastern Time (ET). The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https://ir.zymeworks.com/events-and-pr

    4/16/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 4:27:20 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zymeworks Inc.

    SC 13G - Zymeworks Inc. (0001937653) (Subject)

    11/13/24 4:30:24 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care